SARS-CoV-2 binding to ACE2 triggers pericyte-mediated angiotensin-evoked cerebral capillary constriction

Chanawee Hirunpattarasilp[1,2], Gregory James[1,3], Felipe Freitas[1],

Huma Sethi[4], Josef T. Kittler[1], Jiandong Huo[5,6], Raymond J. Owens[5,6] & David Attwell[1]

[1]Department of Neuroscience, Physiology & Pharmacology

University College London, Gower Street, London, WC1E 6BT, UK

[2]HRH Princess Chulabhorn College of Medical Science, Chulabhorn Royal Academy,

906 Kamphaeng Phet 6 Rd, Talat Bang Khen, Lak Si, Bangkok 10210, Thailand

[3]Department of Neurosurgery, Great Ormond Street Hospital,

London, WC1N 3JH, UK

[4]National Hospital for Neurology and Neurosurgery

Queen Square, London, WC1N 3BG, UK

[5]Division of Structural Biology, Nuffield Department of Medicine

University of Oxford, OX3 7BN, UK

[6]Protein Production UK, The Research Complex at Harwell, and Rosalind Franklin

Institute, Harwell Science & Innovation Campus, Didcot, OX11 0GD, UK

1

Abstract

The SARS-CoV-2 receptor, ACE2, is found on pericytes, contractile cells enwrapping capillaries that regulate brain, heart and kidney blood flow. ACE2 converts vasoconstricting angiotensin II into vasodilating angiotensin-(1-7). In brain slices from hamster, which has an ACE2 sequence similar to human ACE2, angiotensin II alone evoked only a small capillary constriction, but evoked a large pericyte-mediated capillary constriction generated by AT1 receptors in the presence of the SARS-CoV-2 receptor binding domain (RBD). The effect of the RBD was mimicked by blocking ACE2. A mutated non-binding RBD did not potentiate constriction. A similar RBD-potentiated capillary constriction occurred in human cortical slices. This constriction reflects an RBD-induced decrease in the conversion of angiotensin II to angiotensin-(1-7). The clinically-used drug losartan inhibited the RBD-potentiated constriction. Thus AT1 receptor blockers could be protective in SARS-CoV-2 infection by reducing pericyte-mediated blood flow reductions in the brain, and perhaps the heart and kidney.

Introduction

Despite the primary site of infection by SARS-CoV-2 being the respiratory tract, the virus evokes dysfunction of many other organs, including the brain, heart and kidney: 36% of hospitalised patients show neurological symptoms[1], 20% develop myocardial injury[2] and 41% experience acute kidney injury[3]. This could reflect either a spread of virus via the blood[4], or the effects of inflammatory mediators released from the lungs. These effects may contribute to "long Covid", in which clouding of thought and physical exhaustion extend for months after the initial infection.

The receptor[5,6] for SARS-CoV-2 is the enzyme ACE2 (part of the renin-angiotensin system that regulates blood pressure), which converts[7] vasoconstricting angiotensin II into vasodilating angiotensin-(1-7). The Spike protein of SARS-CoV-2 binds to ACE2 to trigger its

endocytosis[6]. For the closely-related SARS virus, binding of only the receptor binding domain (RBD) is sufficient[8] to evoke internalisation of ACE2.

In the heart[9] and brain[10] the main cells expressing ACE2 are pericytes enwrapping capillaries (and some endothelial cells), and pancreas and lung pericytes also express ACE2[11,12]. Pericytes express contractile proteins and in pathological conditions have been shown to decrease blood flow in the brain[13,14], heart[15] and kidney[16]. Interestingly, a decrease of blood flow has been reported for SARS-CoV-2 infection in the brain[17] and kidney[18]. This could be due to pericyte dysfunction caused by SARS-CoV-2 reducing the activity of ACE2, either by occluding its binding site for angiotensin II (although this is thought not to occur for the related SARS virus[19]) or by promoting internalisation of the enzyme[6,8]. In the presence of angiotensin II (either renally-derived and reaching the brain parenchyma via a compromised blood-brain barrier, or generated by the brain's own renin-angiotensin system[20]), a reduction of ACE2 activity would increase the concentration of vasoconstricting angiotensin II and decrease the concentration of vasodilating angiotensin-(1-7).

Results

Angiotensin II evokes pericyte-mediated capillary constriction via AT1 receptors

To study the effect of the SARS-CoV-2 RBD on cerebral capillary pericyte function, we employed live imaging[21] of brain slices from Syrian golden hamsters. Hamsters have an ACE2 Spike sequence which is more similar to that in humans than is the rat and mouse ACE2 Spike sequence[22]. In particular amino acid 353 in hamsters and humans is a lysine (K) rather than a histidine (H), and this is a key determinant[23] of how well coronaviruses bind to ACE2, making hamsters a good model for studying SARS-CoV-2 effects[22].

We assessed the location of ACE2 and contractile properties of pericytes in the cerebral microvasculature of the hamster, which have not been studied previously (Fig. 1). Immunohistochemistry (IHC) revealed ACE2 to be predominantly expressed in capillary pericytes expressing NG2 and PDGFRβ (Fig. 1a). Quantification of overlap with the pericyte

3

marker PDGFRβ (Fig. 1b) revealed ~75% co-localisation (Fig. 1c), and comparison of expression in capillaries and arterioles showed that capillaries exhibited ~75% of the ACE2 expression (Fig. 1d). These results are consistent with transcriptome and IHC data from mouse and human brain[10] and human heart[9]. As for brain pericytes in rats[24], the thromboxane A_2 analogue U46619 (200 nM) evoked a pericyte-mediated capillary constriction and superimposed glutamate evoked a dilation (Fig. 1e).

Applying angiotensin II (150 nM) evoked a transient constriction, which was inhibited by the AT1 receptor blocker losartan (20 μM, Fig. 1f). Similar angiotensin-evoked pericyte-mediated capillary constriction has been reported in the kidney[25] and retina[26]. The transience of the constriction might reflect receptor desensitisation[27] at this relatively high angiotensin II concentration, or a delayed activation of Mas receptors after the angiotensin II is converted to angiotensin (1-7). Blocking either AT2 receptors (with 1 μM PD123319) or Mas receptors (with 10 μM A779) increased the angiotensin II evoked constriction (approximately 4.5-fold for MasR block, $p<10^{-4}$, Fig. 1g-h), consistent with the AT1R-mediated constriction being opposed by angiotensin II activating AT2 receptors, by angiotensin-(1-7) activating Mas receptors, or by activation of AT2/Mas heteromeric[28] receptors.

SARS-CoV-2 binding potentiates angiotensin II evoked capillary constriction

Acute application of the RBD of Covid 19 (at 0.7 mg/l, or ~22.5 nM, which is approximately 5 times the EC_{50} for binding[29]) for up to 40 mins evoked a small and statistically insignificant reduction of capillary diameter at pericytes (Fig. 2a). On applying a very high level of angiotensin II (2 μM) in the absence of RBD, a transient constriction of capillaries at pericytes was observed (6.3±3.6% in 6 capillaries, not significantly different from the 7.5±1.6% observed using 150 nM angiotensin II in 9 capillaries in Fig. 1f, p=0.73). However, if brain slices were exposed for 30 min to RBD (0.7 mg/l) before the same concentration of angiotensin II was applied together with the RBD, then the angiotensin II evoked a 5-fold larger constriction of 31.5±9.3% in 4 capillaries (significantly different to that seen in the absence of RBD, p=0.019, Fig. 2b). The 30 min pre-exposure period was used in

order to allow time for the large RBD molecule to diffuse into the slice, and was mimicked for the experiments without the RBD. This large constriction-potentiating effect of the RBD was not a non-specific effect on the pericytes' contractile apparatus, because the contractile response to U46619 (200 nM) was unaffected by the RBD (Fig. 2c).

The high concentration of angiotensin II used in Fig. 2b is probably unphysiological and evokes a transient response for reasons that are discussed above. We therefore switched to a lower angiotensin II concentration (50 nM, Fig. 2d), which is more similar to levels found physiologically within the kidney[30,31] and heart[32]. In the presence of the RBD, the constricting response to angiotensin II was increased from an insignificant dilation of -4.5±3.0% to 7.8±3.6% (9 capillaries each, p=0.02), i.e. effectively a constriction of ~12% (from 100*{1 - (92.2%/104.5%)}).

Using surface plasmon resonance to assess binding of RBD mutants to immobilised ACE2, we identified the Y489R mutation as reducing binding by ~94% (Fig. 2e). Applying this mutated RBD (for which glycosylation of the protein is expected to be the same as for the normal RBD) had essentially no effect on the response to angiotensin II (Fig. 2d, f). Thus, the potentiation of the angiotensin II response by the RBD is a result of it binding to ACE2.

The RBD effect is mimicked by blocking ACE2, and blocked by losartan

We hypothesised that the potentiating effect of the RBD on the response to angiotensin II reflects a decrease in the conversion by ACE2 of vasoconstricting angiotensin II into vasodilating angiotensin-(1-7). Such a decrease is expected if RBD binding promotes ACE2 internalisation[6,8] or if it occludes the angiotensin II binding site. We therefore tested the effect of an ACE2 inhibitor (MLN-4760, 1 μM[33]) on the response to 50 nM angiotensin II. This closely mimicked the potentiating effect of the RBD, confirming that the RBD reduces effective ACE2 activity (Fig. 3a, b).

With a view to reducing SARS-CoV-2 evoked capillary constriction and any associated reduction of microvascular blood flow, we tested whether the AT1 receptor

blocker losartan prevented the constricting effect of the RBD. Losartan completely blocked the angiotensin II evoked constriction seen in the presence of the RBD (Fig. 3c, d).

In human SARS-CoV-2 infection it has been suggested that one pathological mechanism is a loss of pericytes caused by viral infection reducing their viability or their interactions with endothelial cells[10]. In a transgenic model of pericyte loss (decreasing PDGFRβ signalling) it was found that endothelial cells upregulated von Willebrand Factor (vWF) production, and thus produced a pro-thrombotic state, which could explain the coagulopathy seen in SARS-CoV-2 patients[10]. However, exposing hamster brain slices to RBD (0.7 mg/l) for 3 hours, in the absence or presence of 50 nM angiotensin II, had no significant effect on pericyte death as assessed by propidium labelling (Fig. 4a). Nevertheless, infection with the actual virus might have more profound effects on pericyte function or viability than does exposure to the RBD.

Capillary constriction is potentiated by SARS-CoV-2 RBD in human capillaries

To assess whether the potentiation of capillary constriction, characterised above in hamsters, also occurs in human capillaries, we employed brain slices made from live human brain tissue that was removed in the course of tumour removal surgery[14]. Consistent with the similar binding[22] of the SARS-CoV-2 RBD to human and hamster ACE2, we found that the RBD greatly potentiated the pericyte-mediated capillary constriction evoked by 50 nM angiotensin II (Fig. 4b-c). SARS-CoV-2 binding would therefore be expected to decrease human cerebral blood flow assuming that, as in rodents, the largest resistance to flow within the brain parenchyma is provided by capillaries[34].

Discussion

The data presented above are consistent with the scheme shown in Fig. 4d-e. Binding of the SARS-CoV-2 RBD to ACE2 in pericytes leads to a decrease in ACE2 activity, either as a result of ACE2 internalisation[6,8] or due to occlusion of the angiotensin II binding site. This leads to an increase in the local concentration of vasoconstricting angiotensin II and a decrease in the concentration of vasodilating angiotensin-(1-7). The resulting

6

activation of contraction via AT_1 receptors in capillary pericytes reduces capillary diameter locally by ~12% when 50 nM angiotensin II is present. As most of the vascular resistance within the brain is located in capillaries[34], this could significantly reduce cerebral blood flow (as occurs following pericyte-mediated constriction after stroke and in Alzheimer's disease[13,14]). Presumably the same mechanism could evoke a similar reduction of blood flow in other organs where pericytes express ACE2 and AT_1 receptors.

From our data it is complicated to predict the magnitude of blood flow reduction expected. If a 12% diameter reduction occurred uniformly in the cerebral vasculature then, by Poiseuille's law for a pure liquid (flow proportional to the 4th power of diameter), the blood flow would be reduced by 40% [from $(1-0.12)^4 = 0.6$]. However pericytes occur only every 30-100 μm (depending on age) along capillaries, suggesting a less profound effect on vascular resistance. On the other hand, the fact that blood contains cells results in its viscosity increasing dramatically at small diameters[35], so that even small pericyte-mediated constrictions can have a large effect. Indeed, complete stalling of blood flow in capillaries can occur as a result of neutrophils (which are less distensible than red blood cells) becoming stuck at narrow parts of the vessel, for example near constricted pericytes[36-38], and this could also transform a small constriction into a much larger reduction of blood flow.

In order for SARS-CoV-2 to evoke pericyte-mediated capillary constriction (or to cause pericyte dysfunction that upregulates vWF production[10]) the virus would need to bind to the ACE2 that is located in pericytes located on the opposite side of the endothelial cell barrier from the blood. Access to pericytes in the brain parenchyma might occur via initial infection of the nasal mucosa and movement from there up the olfactory nerve into the brain[39,40]. Alternatively, movement of the S1 part of the Spike protein across the blood-brain barrier by transcytosis has been reported[41], and crossing the endothelial cell layer may also occur via infection of monocytes (which express ACE2 highly[42] and can cross endothelial cells), or via breakdown of the blood-brain barrier as a result of cytokines released as a result of lung inflammation[43].

7

The reduction of blood flow produced by pericyte-mediated capillary constriction, together with any upregulation of vWF that may occur[10], will tend to promote clotting in the microvasculature. SARS-CoV-2 infection is associated with thrombus formation[44] in large vessels that can be imaged, but it seems possible that thrombi of microvascular origin[45] may add to this, and could perhaps even seed these larger clots. Together, capillary constriction and thrombus formation will reduce the energy supply to the brain and other organs, initiating deleterious changes that probably contribute to the long duration symptoms[46] of "long Covid". Indeed, the decrease of cerebral blood flow occurring during SARS-CoV-2 infection[17] outlasts the acute symptoms[47].

Our data suggest an obvious therapeutic approach, i.e. that the reduction of cerebral and renal blood flow that is observed in SARS-CoV-2 infection[17,18] might be blockable using an AT_1 receptor blocker such as losartan. Interestingly, two clinical trials (clinicaltrials.gov/ct2/show/NCT04312009 and clinicaltrials.gov/ct2/show/NCT04311177) of the possible beneficial effects of losartan in SARS-CoV-2 infection are now under way.

Acknowledgements

Methods

Animals Brain slices (200-300 μm thick) were made from the brains of Syrian golden hamsters (age 5-24 weeks) of both sexes, which were humanely killed (in accordance with UK and EU law) by cervical dislocation after being anaesthetised with isoflurane. In each slice only one pericyte was studied. The constriction evoked by angiotensin II in the presence of the RBD showed overlapping ranges of value for 2 female vessels and 9 male vessels (p=0.67).

Imaging of pericyte mediated constriction Pericytes on cortical capillaries were identified visually as previously described (Fig. S1 of ref. 14) and imaged with a CCD camera as described[21]. Diameter was measured in ImageJ by drawing a line across the vessel between the inner walls of the endothelial cells.

RBD and mutant RBD synthesis Codon optimised Genblocks (IDT Technology) for the receptor binding domain (RBD amino acids 330-532) of SARS-CoV-2 (Genbank MN908947) and human Angiotensin Converting Enzyme 2 (ACE-2, amino acids 19-615) were inserted into the vector pOPINTTGneo (PMID: 25447866) incorporating a C-terminal BirA-His6 tag and pOPINTTGneo-3C-Fc to make C-terminal fusions to Human IgG Fc. The RBD-Y489R mutant was generated by firstly amplifying the RBD-WT gene using oligos TTGneo_RBD_F and RBD-Y489R_R, as well as RBD-Y489R_F and TTGneo_RBD_R; followed by joining the two resulted fragments with TTGneo_RBD_F and TTGneo_RBD_R.

```
TTGneo_RBD_F      5'-gcgtagctgaaaccggcccgaatatcacaaatctttgt-3'
TTGneo_RBD_R      5'-GTGATGGTGATGTTTATTTGTACTTTTTTTCGGTCCGCACAC-3'
RBD-Y489R_F       5'-GGCGTCGAGGGTTTTAACTGTCGCTTCCCACTTCAGTCATACGG-3'
RBD-Y489R_R       5'-CCGTATGACTGAAGTGGGAAGCGACAGTTAAAACCCTCGACGCC-3'
```

The gene carrying the Y489R mutation was then inserted into the vector pOPINTTGneo incorporating a C-terminal His6 tag by Infusion® cloning. The plasmid was sequenced to confirm that the mutation had been introduced successfully. Recombinant protein was transiently expressed in Expi293™ (ThermoFisher Scientific, UK) and purified from culture supernatants by an immobilised metal affinity using an automated protocol implemented on an ÄKTAxpress (GE Healthcare, UK) followed by a Superdex 200 10/300GL column, using

9

phosphate-buffered saline (PBS) pH 7.4 buffer. Recombinant RBD-WT and ACE2-Fc were produced as described[48]. The sequence of the RBD was:

*ETG*P**N**ITNLCPFGEVF**N**ATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKL NDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGN YNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNC<u>Y</u>FPLQSYGFQPTNGVGYQPYR VVVLSFELLHAPATVCGPKKSTN*KHHHHHH*

where the residues in italics are derived from the expression vector. Glycosylated residues are shown in bold (**N**) and the tyrosine that is mutated to arginine (Y489R) in the mutant RBD is shown underlined.

Surface plasmon resonance Experiments were performed using a Biacore T200 system (GE Healthcare). All assays were performed using a Sensor Chip Protein A (GE Healthcare), with a running buffer of PBS pH 7.4, supplemented with 0.005% vol/vol surfactant P20 (GE Healthcare), at 25 °C. ACE2-Fc was immobilized onto the sample flow cell of the sensor chip; the reference flow cell was left blank. RBD-WT or RBD-Y489R (0.1 µM) was injected over the two flow cells, at a flow rate of 30 µl min−1 with an association time of 60 s.

Solutions Brain slices were superfused at 33-36°C with solution containing (mM): 124 NaCl, 2.5 KCl, 1 $MgCl_2$, 2 $CaCl_2$, 1 NaH2PO$_4$, 26 $NaHCO_3$, 10 D-glucose and 0.1 ascorbate, bubbled with 20% O_2/70% N_2/5% CO_2 to ensure a physiological [O_2] was achieved in the slice[13]. The high molecular weight of the RBD (~31 kD) implies it will not diffuse rapidly from the superfusion solution into brain slices so, to apply the RBD, we pre-incubated each slice in solution containing RBD (at 35°C, to allow time for diffusion) prior to placing the slice in the imaging chamber, where it was superfused with the same solution containing the RBD. This 30 min pre-incubation time was mimicked for slices that RBD was not applied to. The same procedure was followed for the mutant RBD.

Immunohistochemistry Hamster brain slices were fixed in 4% paraformaldehyde (PFA) while shaking at room temperature for 20 min and washed 3 times in phosphate-buffered saline (PBS). Antigen retrieval using sodium citrate buffer (consisting of 10 mM sodium citrate, 0.05% Tween 20 and HCl to adjust the pH to 6.0) for 20 min was performed and the

10

slices were left to cool down for 20 min before being washed in PBS for 5 minutes. Brain slices were transferred to blocking solution containing 10% horse serum, 0.2% saponin (Sigma-Aldrich, S7900), 200 mM glycine and 150 μM bovine serum albumin in PBS at 4°C, and shaken overnight. Slices were incubated in the blocking solution with primary antibodies for 72 hours at 4°C with agitation, washed with PBS 4 times, incubated with the secondary antibody overnight at 4°C with agitation and washed again 4 times with PBS. For nucleus counter staining, slices were incubated in PBS containing DAPI (100 ng/ml) for 1 h at room temperature and washed in PBS for 5 min. Primary antibodies used were goat anti-ACE2 (R&D systems, AF933, 1:200), mouse anti-NG2 (Abcam, ab50009, 1:200) and rabbit anti-PDGFRβ (Santa Cruz, sc-432, 1:200). Secondary antibodies used were Alexa fluor 488 donkey anti-goat (Invitrogen, A11055, 1:500), Alexa fluor 555 donkey anti-mouse (Invitrogen, A31570, 1:500) and Alexa fluor 647 donkey anti-rabbit (Invitrogen, A31573, 1:500).

Pericyte death assessment Brain slices (300 μm thick) were incubated for 3 h at 35°C in extracellular solution (bubbled with 20% O_2, 5% CO_2 and 75% N_2) containing 7.5 μM propidium iodide (PI; Sigma-Aldrich, 81845) and isolectin B4 conjugated to Alexa Fluor 647 (Invitrogen, I32450) 3.3 μg/ml, with and without RBD (0.7 mg/l) and/or angiotensin II (50 nM). The slices were fixed with 4% PFA for 1 hour and washed 3 times with PBS, for 10 minutes each time. Nucleus counterstaining was achieved by incubating the slices in PBS containing DAPI (100 ng/ml) for 1 hour, washing 1 time with PBS. Imaging of Z stacks (approximately 320 μm x 320 μm x 20 μm) was performed on a confocal microscope. The first 20 μm from the surface were discarded to exclude cells killed by the slicing procedure.

Human tissue Live human cortical tissue was obtained from the National Hospital for Neurology and Neurosurgery (Queen Square, London). Cortical biopsies were taken from female subjects aged 40–74 undergoing tumour resection. Healthy brain tissue overlying the tumour, which would otherwise have been discarded, was used. Ethical approval was obtained (REC number 15/NW/0568, IRAS ID 180727 (v3.0), "Properties of human pericytes", as approved on 9-10-2018 for extension and amendment) and all patients gave

informed written consent. All tissue handling and storage were in accordance with the Human Tissue Act (2004).

Statistics Data are presented as mean±s.e.m. Data normality was assessed with Shapiro-Wilk or D'Agostino-Pearson omnibus tests. Comparisons of normally distributed data were made using 2-tailed Student's t-tests. Equality of variance was assessed with an F test, and heteroscedastic t-tests were used if needed. Data that were not normally distributed were analysed with Mann-Whitney tests. P values were corrected for multiple comparisons using a procedure equivalent to the Holm-Bonferroni method (for N comparisons, the most significant p value is multiplied by N, the 2nd most significant by N-1, the 3rd most significant by N-2, etc.; corrected p values are significant if they are less than 0.05).

.

References

1. Mao, L. et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. *JAMA Neurol.* **77**, 683-690 (2020).

2. Shi, S. et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With SARS-CoV-2 in Wuhan, China. *JAMA Cardiol.* **5**, 802-810 (2020).

3. Hansrivijit, P., Gadhiya, K.P., Gangireddy, M. & Goldman, J.D. Risk Factors, Clinical Characteristics, and Prognosis of Acute Kidney Injury in Hospitalized SARS-CoV-2 Patients: A Retrospective Cohort Study. *Medicines (Basel)* **8**, E4 (2020).

4. Lescure, F-X., et al. Clinical and virological data of the first cases of SARS-CoV-2 in Europe: a case series. *Lancet Infect. Dis.* **20**, 697-706 (2020).

5. Hoffmann, M. et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* **181**, 271-280 (2020).

6. Ou, X. et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. *Nat. Commun.* **11**, 1620 (2020).

7. Santos, R.A.S. et al. The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7). *Physiol. Rev.* **98**, 505-553 (2018).

8. Wang, S. et al. Endocytosis of the receptor-binding domain of SARS-CoV spike protein together with virus receptor ACE2. *Virus Res.* **136**, 8-15 (2008).

9. Chen, L., Li, X., Chen, M., Feng, Y. & Xiong, C. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. *Cardiovasc. Res.* **116**, 1097-1100 (2020).

10. He, L. et al. Pericyte-specific vascular expression of SARS-CoV-2 receptor ACE2 – implications for microvascular inflammation and hypercoagulopathy in SARS-CoV-2. *bioRxiv* https://www.biorxiv.org/content/10.1101/2020.05.11.088500v2.full (2020)

11. Fignani, D. et al. SARS-CoV-2 Receptor Angiotensin I-Converting Enzyme Type 2 (ACE2) Is Expressed in Human Pancreatic β-Cells and in the Human Pancreas Microvasculature. *Front. Endocrinol.* **11**, 596898 (2020).

12. He, L. et al. Data Descriptor: Single cell RNAseq of mouse brain and lung vascular and vessel-associated cell types. *Scientific Data* **5**, 180160 (2018).

13. Hall C.N. et al. Capillary pericytes regulate cerebral blood flow in health and disease. *Nature* **508**, 55-60 (2014).

14. Nortley, R. et al. Amyloid β oligomers constrict human capillaries in Alzheimer's disease via signaling to pericytes. *Science* **365**, eaav9518 (2019).

15. O'Farrell, F. et al. Capillary pericytes mediate coronary no-reflow after myocardial ischaemia. *eLife* **6**, e29280 (2017).

16. Freitas, F. & Attwell, D. Descending vasa recta pericytes mediate medullary no-reflow after renal ischaemia. *Proc. Physiol. Soc.* **43**, C114 (2019).

17. Soldatelli, M.D. et al. Neurovascular and perfusion imaging findings in coronavirus disease 2019: Case report and literature review. *Neuroradiol. J.* **33**, 368-373 (2020).

18. Watchorn, J., Huang, D.Y., Joslin, J., Bramham, K. & Hutchings, S.D. Critically ILL SARS-CoV-2 Patients With Acute Kidney Injury Have Reduced Renal Blood Flow and Perfusion Despite Preserved Cardiac Function; A Case-Control Study Using Contrast Enhanced Ultrasound. *Shock* **55**, 479-487 (2021).

19. Li, F., Li, W., Farzan, M. & Harrison, S.C. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. *Science* **309**, 1864-1868 (2005).

20. Jackson, L., Eldashan, W., Fagan, S.C. & Ergul, A. Within the Brain: The Renin Angiotensin System. *Int. J. Mol. Sci.* **19**, 876 (2018).

21. Mishra, A. et al. Imaging pericytes and capillary diameter in brain slices and isolated retinae. *Nat. Protoc.* **9**, 323-336 (2014).

22. Chan, J.F. et al. Simulation of the Clinical and Pathological Manifestations of Coronavirus Disease 2019 (SARS-CoV-2) in a Golden Syrian Hamster Model: Implications for Disease Pathogenesis and Transmissibility. *Clin. Infect. Dis.* **71**, 2428-2446 (2020).

23. Frieman, M. et al., Molecular Determinants of Severe Acute Respiratory Syndrome Coronavirus Pathogenesis and Virulence in Young and Aged Mouse Models of Human Disease. *J. Virol.* **86**, 884-897 (2012).

24. Mishra, A. et al. Astrocytes mediate neurovascular signaling to capillary pericytes but not to arterioles. *Nat. Neurosci.* **19**, 1619-1627 (2016).

25. Pallone, T.L. & Silldorff, E.P. Pericyte regulation of renal medullary blood flow. *Exp..Nephrol.* **9**, 165-170 (2001).

26. Schönfelder, U. Hofer, A., Paul, M. & Funk, R.H. In situ observation of living pericytes in rat retinal capillaries. *Microvasc. Res.* **56**, 22-29 (1998).

27. Hunyady, L., Catt, K.J., Clark, A.J.L. & Gáborik, Z. Mechanisms and functions of AT_1 receptor internalization. *Regulatory peptides* **91**, 29-44 (2000).

28. Patel, S. & Hussain, T. Dimerization of AT_2 and Mas Receptors in Control of Blood Pressure. *Curr. Hypertens. Rep.* **20**, 41 (2018).

29. Tai, W. et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. *Cell. Molec. Immunol.* **17**, 613-620 (2020).

30. Seikaly, M.G., Arant, B.S.Jr. & Seney, F.D.Jr. Endogenous angiotensin concentrations in specific intrarenal compartmentsof the rat. *J. Clin. Invest.* **86**, 1352-1357 (1990).

31. Siragy, H.M., Howell, N.L., Ragsdale, N.V. & Carey, R.M. Renal interstitial fluid angiotensin. Modulation by anesthesia, epinephrine, sodium depletion, and renin inhibition. *Hypertension* **25**, 1021-1024 (1995).

32. Dell'Italia, L.J. et al. Compartmentalization of angiotensin II generation in the dog heart. Evidence for independent mechanisms in intravascular and interstitial spaces. *J. Clin. Invest.* **100**, 253-258 (1997).

33. Ye, M. et al Murine recombinant angiotensin-converting enzyme 2: effect on angiotensin II-dependent hypertension and distinctive angiotensin-converting enzyme 2 inhibitor characteristics on rodent and human angiotensin-converting enzyme 2. *Hypertension* **60**, 730-740 (2012).

34. Gould, I.G., Tsai, P., Kleinfeld, D. & Linninger, A. The capillary bed offers the largest hemodynamic resistance to the cortical blood supply. *J. Cereb. Blood Flow Metab.* **37**, 52-68 (2017).

35. Pries, A.R., Neuhaus, D. & Gaehtgens, P. Blood viscosity in tube flow: dependence on diameter and hematocrit. *Am. J. Physiol.* **263**, H1770-1778 (1992).

36. Cruz Hernández, J.C. et al. Neutrophil adhesion in brain capillaries reduces cortical blood flow and impairs memory function in Alzheimer's disease mouse models. *Nat. Neurosci.* **22**, 413–420 (2019).

37. Shager, B. & Brown, C.E. Susceptibility to capillary plugging can predict brain region specific vessel loss with aging. J. Cereb. Blood Flow Metab. **40**, 2475-2490 (2020).

38. Korte, N., Nortley, R. & Attwell, D. Cerebral blood flow decrease as an early pathological mechanism in Alzheimer's disease. *Acta Neuropathol.* **140**, 793-810 (2020).

39. Perlman, S., Sun, N. & Barnett, E.M. Spread of MHV-JHM from nasal cavity to white matter of spinal cord. Transneuronal movement and involvement of astrocytes. *Adv. Exp. Med. Biol.* **380**, 73-78 (1995).

40. Meinhardt, J. et al. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with SARS-CoV-2. *Nat. Neurosci.* **24**, 168-175 (2020).

41. Rhea, E.M. et al. The S1 protein of SARS-CoV-2 crosses the blood-brain barrier in mice. *Nat. Neurosci.* **24**, 368-378 (2021).

42. Zhang, D. et al. COVID- 19 infection induces readily detectable morphologic and inflammation-related phenotypic changes in peripheral blood monocytes. *J. Leukocyte Biol.* **109**, 13-22 (2021).

43. Kumar, D. et al. Possible routes of SARS-CoV-2 invasion in brain: In context of neurological symptoms in SARS-CoV-2 patients. *J. Neurosci. Res.* **98**, 2376-2383 (2020).

44. Klok, F.A. et al. Incidence of thrombotic complications in critically ill ICU patients with SARS-CoV-2. *Thromb. Res.* **191**, 145-147 (2020).

45. Saitta, L. et al. Brain microvascular occlusive disorder in SARS-CoV-2: a case report. *Neurol. Sci.* **41**, 3401-3404 (2020).

46. Mahase, E. SARS-CoV-2: what do we know about "long Covid"? *BMJ* **370**, m2815 (2020).

47. Qin, Y. et al. Long-term micro-structure and cerebral blood flow changes in patients recovered from COVID-19 without neurological manifestations. *J. Clin. Invest.* doi: 10.1172/JCI147329 (2021).

48. Huo, J., et al. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. *Nat. Struct. Mol. Biol.* **27**, 846-854 (2020).

Figure Legends

Fig. 1. Cerebral pericytes express ACE2 and constrict capillaries in response to Ang II

(**a**) Labelling of hamster cortical slice with antibodies to the SARS-CoV-2 receptor ACE2, the pericyte markers NG2 and PDGFRβ, and with DAPI to label nuclei (**b**) Lower magnification maximum intensity projection of ACE2 and PDGFRβ labelling, showing capillaries and penetrating arteriole. (**c**) Integrated ACE2 labelling overlapping with a binarised mask of PDGFRβ labelling and with the inverse of this mask (numbers on bars are image stacks). (**d**) Integrated ACE2 labelling over capillaries versus penetrating arterioles (PA). (**e**) Average normalised diameter changes (mean±s.e.m.) at 5 pericytes in brain slices exposed to the thromboxane A_2 analogue U46619 (200 nM), and then with the neurotransmitter glutamate (500 μM) superimposed. (**f**) Average normalised diameter changes at 9 pericytes exposed to 150 nM angiotensin II alone (aCSF), and 10 pericytes exposed to angiotensin II in the presence of the AT_1R blocker losartan (20 μM). (**g**) As in (f) (aCSF plot is the same) but showing angiotensin II response in the presence of the AT_2R blocker PD123319 (1 μM) or the Mas receptor blocker A779 (10 μM). (**h**) Peak constriction evoked by angiotensin II in different conditions (number of pericytes studied shown on bars).

Fig. 2. The SARS-CoV-2 RBD potentiates angiotensin-evoked capillary constriction

(**a**) Perfusion of brain slices with RBD (0.7 mg/l) has no significant effect on capillary diameter at pericytes (mean±s.e.m.; n=5 for aCSF and 6 for RBD). (**b**) After preincubation in aCSF for 30 mins, applying 2 μM angiotensin II evokes a small transient capillary constriction at pericytes (n=6), while including RBD (0.7 mg/l) in the solutions results in an ~5-fold larger response to angiotensin II (n=4; peak constriction plotted is slightly larger than the mean value quoted in the text because the latter was averaged over 5 frames and here only every 5th frame is plotted). (**c**) RBD has no effect on constriction evoked by 200 nM U46619 (n=6 for aCSF and 5 for RBD). (**d**) Response to 50 nM angiotensin II after pre-

incubation and subsequent perfusion with aCSF, or aCSF containing RBD or Y489R mutant RBD (n=9 for each). (**e**) Surface plasmon resonance responses for RBD and mutant (Y489R) RBD binding to immobilised human ACE2. (**f**) Mean constriction between t = 29.67 and 30.00 min in (d).

Fig. 3. The effect of RBD is mimicked by blocking ACE2 and reduced by losartan

(**a**) Capillary constriction at pericytes in response to 50 nM angiotensin II in the absence (n=9) and presence (n=9) of the RBD (mean±s.e.m., replotted from Fig. 2d) and in the presence of the ACE2 inhibitor MLN4760 (1 μM, n=9). (**b**) Constriction in (a) between t = 29.67 and 30.00 min. (**c**) Response to 50 nM angiotensin II after 30 mins incubation in (and continued perfusion with) aCSF containing RBD (0.7 mg/l, n=9, from Fig. 2d) or additionally losartan (20 μM, n=10). (**d**) Constriction in (c) between t = 29.67 and 30.00 min.

Fig. 4. The SARS-CoV-2 RBD potentiates constriction in human capillaries

(**a**) Percentage of pericytes dead (assessed with propidium iodide) in hamster brain slices (numbers on bars) after 3 hours incubation in aCSF, or aCSF containing 50 nM angiotensin II and/or RBD (0.7 mg/l). (**b**) Effect of 50 nM angiotensin on capillary diameter (mean±s.e.m.) at pericytes in human brain slices in the presence (n=4) and absence (n=5) of the RBD (30 mins pre-incubation). (**c**) Mean constriction at 30 mins) from data in (b). (**d-e**) Likely mode of operation of RBD binding to ACE2. (**d**) Normally, angiotensin II (e.g. generated by the brain renin-angiotensin system (RAS)) can act on vasoconstricting AT_1 receptors or vasodilating AT_2 receptors, and is converted (pink arrow) by pericyte ACE2 to vasodilating angiotensin-(1-7) that acts via Mas receptors. (**e**) In the presence of SARS-CoV-2, binding of the Spike protein RBD to ACE2 leads to its internalisation (see Introduction), reducing the conversion of angiotensin II to angiotensin-(1-7). Angiotensin II (derived from the brain RAS or from the peripheral RAS) will then evoke a different balance of responses via the receptors shown, generating a larger constriction because of less activation of Mas receptors.

19

**a**

ACE2 | NG2 | PDGFRβ | ACE2 NG2 DAPI PDGFRβ

50 μm

b

ACE2 | PDGFRβ

100 μm

c

Percentage of ACE2 expression (%)

p < 0.0001

18 | 18

+ | −

PDGFRβ

d

Percentage of ACE2 expression (%)

p = 8.1×10⁻⁷

10 | 10

Cap | PA

e

Normalised vessel diameter

Glutamate (500 μM)

U46619 (200 nM)

p = 0.0014   p = 0.006

Time (min)

f

Normalised vessel diameter

Angiotensin II (150 nM)

Losartan (AT1R inhibitor)

aCSF

Time (min)

g

Normalised vessel diameter

Angiotensin II (150 nM)

aCSF

PD123319 (AT2R inhibitor)

A779 (MasR inhibitor)

Time (min)

h

Peak constriction (%)

p < 0.0001

p = 0.79

p = 0.027

9 | 10 | 9 | 5

aCSF | Losartan | PD123319 | A779

Fig. 1

Fig. 2

Fig. 3

a

p=0.64

p=0.61   p=0.45

% death

aCSF | aCSF + AngII | RBD | RBD + AngII
6 | 6 | 6 | 6

b

Angiotensin II (50 nM)

Normalised vessel diameter

aCSF

RBD

Time (min)

c

p=0.0027

Constriction at steady state (%)

4

5

aCSF   RBD

d

AT II

Ang (1-7)

AT1R   AT2R   Mas R   ACE 2

Constrict   Dilate

Net constriction

Pericyte

e

AT II

COVID-19

Spike protein

RBD

AT1R   AT2R   Mas R   ACE 2

Constrict   Dilate

Internalised ACE 2

Potentiated constriction

Pericyte

Fig. 4